Stocks · News reference
Genmab Announces Positive Phase 3 Results for Petosemtamab Combination
Genmab reported that its Phase 3 LiGeR-HN1 trial of petosemtamab in combination with pembrolizumab met both primary endpoints in patients with first-line PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AlphaValue/Baader Europe Downgrades Genmab to Reduce
AlphaValue/Baader Europe has downgraded its rating for Genmab A/S to "Reduce" on October 28, 2026.
TD Cowen Maintains Buy on Genmab, Raises Price Target to $52